| Name | Title | Contact Details |
|---|
Great Lakes Health Plan (GLHP) has been offering health care services to members eligible for Medicaid in the State of Michigan since March 1996. Our service area covers members living in 23 counties, including: Allegan, Berrien, Branch, Cass, Calhoun,
Merrill Gardens LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Chase Brexton is an equal opportunity employer committed to providing all employees, patients, applicants, and visitors with a safe and supportive environment. Everyone is welcomed and accepted, regardless of race, gender, nation of origin, sexual orientation, gender identity, marital status, religion, socio-economic status, veteran status, or disability. Minority applicants are strongly encouraged to apply. Part of our vision at Chase Brexton is to empower our staff and foster a culture that promotes staff development and satisfaction. We believe our staff is key to achieving our mission to provide compassionate, quality health care that honors diversity, inspires wellness, and improves our communities. Our work is not possible without a strong, devoted, and talented staff. Chase Brexton offers a comprehensive benefits package including medical and dental insurance, vacation, sick leave, paid holidays, long- and short-term disability, life insurance, tuition reimbursement, an Employee Assistance Program, and a tax-free retirement plan with company matching contributions. All in a professional, supportive environment.
Dava Pharmaceuticals is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Fort Lee, NJ. To find more information about Dava Pharmaceuticals, please visit www.davapharma.com
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.